Inventor · disambiguated record
Frederick L. Hall
Also filed as: HALL FREDERICK L
29 granted patents·15 pending applications·298 citations·filing 1995–2022
96Inventor score
Files withUNIV SOUTHERN CALIFORNIA18HALL FREDERICK L8COUNTERPOINT BIOMEDICA LLC6GORDON ERLINDA M4DELTA NEXT GENE LLC3
Top patents by PatentIndex Score
44 records- 0192US7820157B2Transgene delivering retrovirus targeting collagen exposed at site of tissue injuryUNIV SOUTHERN CALIFORNIA·Filed 2008·Granted Oct 26, 2010·12 cites·3 claims
- 0288US7708986B2Targeted vectors for cancer immunotherapyUNIV SOUTHERN CALIFORNIA·Filed 2006·Granted May 4, 2010·6 cites·8 claims
- 0388US7347998B2Method of delivering therapeutic agents to site of tissue injuryUNIV SOUTHERN CALIFORNIA·Filed 2004·Granted Mar 25, 2008·19 cites·11 claims
- 0487US6410015B1Gene therapy methods using bone marrow-derived cells expressing blood clotting factorsUNIV SOUTHERN CALIFORNIA·Filed 2000·Granted Jun 25, 2002·21 cites·4 claims
- 0584US11325958B2Cyclin G1 inhibitors and related methods of treating cancerDELTA NEXT GENE LLC·Filed 2018·Granted May 10, 2022·2 cites·18 claims
- 0684US6352972B1Bone morphogenetic proteins and their use in bone growthFiled 1997·Granted Mar 5, 2002·57 cites·2 claims
- 0783US8530441B2Transgene delivering retrovirus targeting collagen exposed at site of tissue injuryHALL FREDERICK L·Filed 2012·Granted Sep 10, 2013·5 cites·12 claims
- 0881US7459541B2Matrix-targeted fusion polypeptides for tissue regeneration and wound healingUNIV SOUTHERN CALIFORNIA·Filed 2003·Granted Dec 2, 2008·17 cites·2 claims
- 0980US11273206B2Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptidesCOUNTERPOINT BIOMEDICA LLC·Filed 2019·Granted Mar 15, 2022·1 cites·18 claims
- 1080US6864082B2Modified viral surface proteins for binding to extracellular matrix componentsUNIV SOUTHERN CALIFORNIA·Filed 2001·Granted Mar 8, 2005·9 cites·2 claims
- 1180US6825033B2Mutated cyclin G1 proteinUNIV SOUTHERN CALIFORNIA·Filed 2001·Granted Nov 30, 2004·9 cites·10 claims
- 1279US10981980B2Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cellsCOUNTERPOINT BIOMEDICA LLC·Filed 2017·Granted Apr 20, 2021·1 cites·10 claims
- 1379US7605142B2Expression of cyclin G1 in tumorsUNIV SOUTHERN CALIFORNIA·Filed 2006·Granted Oct 20, 2009·2 cites·7 claims
- 1479US6387663B1Targeting pharmaceutical agents to injured tissuesUNIV SOUTHERN CALIFORNIA·Filed 1998·Granted May 14, 2002·40 cites·4 claims
- 1577US10913779B2Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infectionsCOUNTERPOINT BIOMEDICA LLC·Filed 2018·Granted Feb 9, 2021·1 cites·21 claims
- 1677US6955898B2Targeting pharmaceutical agents to injured tissuesUNIV SOUTHERN CALIFORNIA·Filed 2002·Granted Oct 18, 2005·9 cites·25 claims
- 1776US6277369B1Factor 1X delivery method using bone marrow-derived cellsUNIV SOUTHERN CALIFORNIA·Filed 2000·Granted Aug 21, 2001·6 cites·4 claims
- 1874US12173041B2Cyclin G1 inhibitors and related methods of treating cancerDELTA NEXT GENE LLC·Filed 2022·Granted Dec 24, 2024·0 cites·12 claims
- 1972US8148509B2Transgene delivering retrovirus targeting collagen exposed at site of tissue injuryHALL FREDERICK L·Filed 2010·Granted Apr 3, 2012·1 cites·7 claims
- 2072US8052966B2Methods and compositions for treating metastatic cancerUNIV SOUTHERN CALIFORNIA·Filed 2004·Granted Nov 8, 2011·5 cites·11 claims
- 2172US2015031625A1Targeted vectors for cancer immunotherapyUNIV SOUTHERN CALIFORNIA·Filed 2014·Application pending·0 cites
- 2269US7795023B2Identification of a pluripotent pre-mesenchymal, pre-hematopoietic progenitor cellUNIV SOUTHERN CALIFORNIA·Filed 2003·Granted Sep 14, 2010·3 cites·8 claims
- 2368US6844191B2Osteogenic cell growth using a TGFβ1-von Willebrand's factor fusion proteinUNIV SOUTHERN CALIFORNIA·Filed 2002·Granted Jan 18, 2005·2 cites·4 claims
- 2467US2022041696A1Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cellsCOUNTERPOINT BIOMEDICA LLC·Filed 2021·Application pending·0 cites
- 2561US10420820B2Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptidesCOUNTERPOINT BIOMEDICA LLC·Filed 2015·Granted Sep 24, 2019·0 cites·20 claims
- 2661US5800811AArtificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding siteFiled 1995·Granted Sep 1, 1998·64 cites·20 claims
- 2761US2022017586A1Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infectionsCOUNTERPOINT BIOMEDICA LLC·Filed 2021·Application pending·0 cites
- 2860US2023080185A1Damage-targeted treatments of diseaseDELTA NEXT GENE LLC·Filed 2022·Application pending·0 cites
- 2958US9017659B2Pathotropic targeted gene delivery system for cancer and other disordersHALL FREDERICK L·Filed 2007·Granted Apr 28, 2015·0 cites·7 claims
- 3058US2002177571A1Targeted vectors for cancer immunotherapyFiled 2001·Application pending·0 cites
- 3155US8828378B2Targeted vectors for cancer immunotherapyGORDON ERLINDA M·Filed 2010·Granted Sep 9, 2014·0 cites·6 claims
- 3255US2003086927A1Expression of cyclin G1 in tumorsUNIV SOUTHERN CALIFORNIA·Filed 2002·Application pending·0 cites
- 3353US2021346520A1Methods of using intravenous rexin-g: a tumor-targeted retrovector encoding a dominant-negative cyclin g1 (ccng1) inhibitor for advanced pancreatic cancerGORDON ERLINDA M·Filed 2021·Application pending·0 cites
- 3452US2009093407A1Matrix-targeted fusion polypeptides for tissue regeneration and wound healingHALL FREDERICK L·Filed 2008·Application pending·0 cites
- 3550US2007178066A1Pathotropic targeted gene delivery system for cancer and other disordersHALL FREDERICK L·Filed 2006·Application pending·0 cites
- 3650US2021299276A1Methods of exploiting oncogenic drivers along the human cyclin g1 pathway for cancer gene therapyGORDON ERLINDA M·Filed 2021·Application pending·0 cites
- 3750US2009123428A1Pathotropic targeted gene delivery system for cancer and other disordersHALL FREDERICK L·Filed 2008·Application pending·0 cites
- 3849US8871734B2Transgene delivering retrovirus targeting collagen exposed at site of tissue injuryEPEIUS BIOTECHNOLOGIES·Filed 2013·Granted Oct 28, 2014·0 cites·18 claims
- 3949US7078483B2Retroviral vectors including modified envelope escort proteinsUNIV SOUTHERN CALIFORNIA·Filed 2002·Granted Jul 18, 2006·0 cites·2 claims
- 4049US6063593ATGFβ1 responsive bone marrow derived cells to express a recombinant proteinUNIV SOUTHERN CALIFORNIA UNIVE·Filed 1996·Granted May 16, 2000·6 cites·16 claims
- 4149US2022184228A1Methods of promoting long-term survival of patients with advanced chemotherapy-resistant malignanciesGORDON ERLINDA M·Filed 2020·Application pending·0 cites
- 4245US2006292121A1Retroviral vectors including modified envelope escort proteinHALL FREDERICK L·Filed 2006·Application pending·0 cites
- 4344US2011052670A1Identification of a pluripotent pre-mesenchymal, pre-hematopoietic progenitor cellUNIV SOUTHERN CALIFORNIA·Filed 2010·Application pending·0 cites
- 4438US2012027727A1Targeted nanoparticles for cancer and other disordersHALL FREDERICK L·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Frederick L. Hall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →